CD274 and cancer: In three different phase 3 clinical trials, namely JUPITER-02 (NPC), JUPITER-06 (ESCC) and CHOICE-01 (NSCLC), that toripalimab in combination with chemotherapy was generally efficacious in PD-L1 positive and PD-L1 negative/low cancer patients in subgroup analyses (PD-L1 screen: JS311 IHC assay).